ClinicalTrials.gg
CompletedNCT05040295Updated Aug 21, 2023Results posted

A Single Dose Study To Test Two Pediatric Forms Of Ritlecitinib Compared With Adult Ritlecitinib In Healthy Adults

A Phase 1 interventional study of ritlecitinib and ritlecitinib in Healthy Participants, sponsored by Pfizer. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-08-21.

Sponsored by Pfizer · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

A phase I, single dose study to test two forms of pediatric ritlecitinib compared to adult ritlecitinib in healthy adults aged 18-55 years old. Approximately 12 adults will participate for approximately 2.5 months.

02

Conditions studied

  • Healthy Participants
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female participants who are healthy as determined by medical evaluation including a detailed medical history, complete (full) physical examination, which includes BP and pulse rate measurement, clinical laboratory tests, and 12-lead .
  • of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lb).

Exclusion criteria

Exclusion Criteria:

  • Evidence or history of hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, dermatological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).
  • Any condition possibly affecting drug absorption (eg, gastrectomy, cholecystectomy).
  • Known immunodeficiency disorder, including positive serology for at screening, or a first degree relative with a hereditary immunodeficiency
  • Infection with or viruses.
  • History of any lymphoproliferative disorder
  • Known present or a history of other than a successfully treated or excised nonmetastatic basal cell or squamous cell cancer of the skin or cervical carcinoma in situ
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Treatment sequence 1

    Treatment sequence 1 will receive a single 30 milligrams (mg) ritlecitinib intact adult capsule during the first period, three 10 mg ritlecitinib pediatric capsules during the second period and 30 mg ritlecitinib spray congealed beads in the third period.

    Drug: ritlecitinib

  • Experimental
    Treatment Sequence 2

    Treatment sequence 2 will receive three 10 mg ritlecitinib pediatric capsules during the first period, a single 30 mg intact adult capsule during the second period and 30 mg ritlecitinib spray congealed beads in the third period.

    Drug: ritlecitinib

Interventions

06

What researchers measure

Primary outcomes

  1. Area Under the Plasma Concentration-Time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) for Ritlecitinib

    Plasma AUCinf for ritlecitinib is reported. AUCinf was calculated as \[AUClast+(Clast\*/kel)\], where AUClast is the area under the plasma concentration-time profile from time 0 to the time of the Clast, Clast is the last quantifiable concentration, Clast\* is the predicted plasma concentration at the last quantifiable time point estimated from the log-linear regression analysis, and kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.

    Time frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, and 24 hours post dose on Day 1 in each period

  2. Maximum Plasma Concentration (Cmax) for Ritlecitinib

    Plasma Cmax for ritlecitinib is reported.

    Time frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, and 24 hours post dose on Day 1 in each period

Secondary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (All Causalities and Treatment-Related)

    An adverse event (AE) was any untoward medical occurrence attributed to study drug in a participant who received study drug. Treatment-related AE was any untoward medical occurrence attributed to study treatment in a participant who received study treatment. Treatment-emergent AEs (TEAEs) = between first dose of study treatment and up to 35 days after last dose that were absent before treatment or that worsened relative to pretreatment state. A serious AE (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-related AEs and SAEs were determined by the investigator. Severe=an event that prevents normal everyday activities.

    Time frame: Post first dose of study intervention on Period 1 Day 1 up to 35 days post last dose of study intervention on Period 3 Day 1 (maximum of 40 days)

  2. Number of Participants With Laboratory Abnormalities Without Regard to Baseline Abnormality

    Following parameters were analyzed for laboratory examination: hematology (hemoglobin, hematocrit, red blood cell count, platelet count, white blood cell count, total neutrophils, eosinophils, monocytes, basophils, lymphocytes, etc), chemistry (fasting glucose, calcium, sodium, potassium, chloride, total bilirubin, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, uric acid, total protein, albumin, etc), and urinalysis (glucose, protein, blood, ketones, nitrites, leukocyte esterase, etc). Baseline = the last pre-dose measurement before Period 1 Day 1 (ie, first dose of study intervention). Laboratory abnormalities meeting pre-defined criteria are reported for this outcome measure. ULN=upper limit of normal. LLN=lower limit of normal. HPF=high-powered field. mEq=milliequivalent. L=liter.

    Time frame: Baseline up to Period 3 Day 2 (maximum of 7 days)

07

Results

Posted Aug 21, 2023

Participant flow

Period 1
Participant flow — Period 1
Milestone[Sequence 1] Ritlecitinib: Intact Adult Capsule=>Pediatric Capsules=>Spray Congealed Beads[Sequence 2] Ritlecitinib: Pediatric Capsules=>Intact Adult Capsule=>Spray Congealed Beads
Started66
Completed66
Not completed00
Period 2
Participant flow — Period 2
Milestone[Sequence 1] Ritlecitinib: Intact Adult Capsule=>Pediatric Capsules=>Spray Congealed Beads[Sequence 2] Ritlecitinib: Pediatric Capsules=>Intact Adult Capsule=>Spray Congealed Beads
Started66
Completed66
Not completed00
Period 3
Participant flow — Period 3
Milestone[Sequence 1] Ritlecitinib: Intact Adult Capsule=>Pediatric Capsules=>Spray Congealed Beads[Sequence 2] Ritlecitinib: Pediatric Capsules=>Intact Adult Capsule=>Spray Congealed Beads
Started66
Completed66
Not completed00

Outcome measures

PrimaryArea Under the Plasma Concentration-Time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) for Ritlecitinib

Plasma AUCinf for ritlecitinib is reported. AUCinf was calculated as \[AUClast+(Clast\*/kel)\], where AUClast is the area under the plasma concentration-time profile from time 0 to the time of the Clast, Clast is the last quantifiable concentration, Clast\* is the predicted plasma concentration at the last quantifiable time point estimated from the log-linear regression analysis, and kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.

Time frame:
Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, and 24 hours post dose on Day 1 in each period
Reported as:
Geometric mean · nanograms*hours/milliliter (ng*hr/mL)
Area Under the Plasma Concentration-Time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) for Ritlecitinib
nanograms*hours/milliliter (ng*hr/mL)Treatment A: Ritlecitinib 30 mg Intact Adult CapsuleTreatment B: Ritlecitinib 3*10 mg Pediatric CapsulesTreatment C: Ritlecitinib 30 mg Spray Congealed Beads
Area Under the Plasma Concentration-Time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) for Ritlecitinib361.1 ± 39370.1 ± 40385.1 ± 38
Statistical analysis
  • Treatment A: Ritlecitinib 30 mg Intact Adult Capsule vs Treatment B: Ritlecitinib 3*10 mg Pediatric Capsules · Ratio of adjust geometric means: 102.50 · 90% CI 94.21 to 111.51Reference = Treatment A Test = Treatment B Ratio=Test/Reference
  • Treatment A: Ritlecitinib 30 mg Intact Adult Capsule vs Treatment C: Ritlecitinib 30 mg Spray Congealed Beads · Ratio of adjust geometric means: 106.65 · 90% CI 100.07 to 113.66Reference = Treatment A Test = Treatment C Ratio=Test/Reference
PrimaryMaximum Plasma Concentration (Cmax) for Ritlecitinib

Plasma Cmax for ritlecitinib is reported.

Time frame:
Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, and 24 hours post dose on Day 1 in each period
Reported as:
Geometric mean · ng/mL
Maximum Plasma Concentration (Cmax) for Ritlecitinib
ng/mLTreatment A: Ritlecitinib 30 mg Intact Adult CapsuleTreatment B: Ritlecitinib 3*10 mg Pediatric CapsulesTreatment C: Ritlecitinib 30 mg Spray Congealed Beads
Maximum Plasma Concentration (Cmax) for Ritlecitinib197.4 ± 38199.6 ± 37177.9 ± 30
Statistical analysis
  • Treatment A: Ritlecitinib 30 mg Intact Adult Capsule vs Treatment B: Ritlecitinib 3*10 mg Pediatric Capsules · Ratio of adjust geometric means: 101.12 · 90% CI 88.25 to 115.87Reference = Treatment A Test = Treatment B Ratio=Test/Reference
  • Treatment A: Ritlecitinib 30 mg Intact Adult Capsule vs Treatment C: Ritlecitinib 30 mg Spray Congealed Beads · Ratio of adjust geometric means: 90.11 · 90% CI 78.49 to 103.44Reference = Treatment A Test = Treatment C Ratio=Test/Reference
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (All Causalities and Treatment-Related)

An adverse event (AE) was any untoward medical occurrence attributed to study drug in a participant who received study drug. Treatment-related AE was any untoward medical occurrence attributed to study treatment in a participant who received study treatment. Treatment-emergent AEs (TEAEs) = between first dose of study treatment and up to 35 days after last dose that were absent before treatment or that worsened relative to pretreatment state. A serious AE (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-related AEs and SAEs were determined by the investigator. Severe=an event that prevents normal everyday activities.

Time frame:
Post first dose of study intervention on Period 1 Day 1 up to 35 days post last dose of study intervention on Period 3 Day 1 (maximum of 40 days)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (All Causalities and Treatment-Related)
ParticipantsTreatment A: Ritlecitinib 30 mg Intact Adult CapsuleTreatment B: Ritlecitinib 3*10 mg Pediatric CapsulesTreatment C: Ritlecitinib 30 mg Spray Congealed Beads
Participants with AEs (All Causalities)211
Participants with AEs (Treatment Related)000
Participants with SAEs000
Participants with Severe AEs000
SecondaryNumber of Participants With Laboratory Abnormalities Without Regard to Baseline Abnormality

Following parameters were analyzed for laboratory examination: hematology (hemoglobin, hematocrit, red blood cell count, platelet count, white blood cell count, total neutrophils, eosinophils, monocytes, basophils, lymphocytes, etc), chemistry (fasting glucose, calcium, sodium, potassium, chloride, total bilirubin, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, uric acid, total protein, albumin, etc), and urinalysis (glucose, protein, blood, ketones, nitrites, leukocyte esterase, etc). Baseline = the last pre-dose measurement before Period 1 Day 1 (ie, first dose of study intervention). Laboratory abnormalities meeting pre-defined criteria are reported for this outcome measure. ULN=upper limit of normal. LLN=lower limit of normal. HPF=high-powered field. mEq=milliequivalent. L=liter.

Time frame:
Baseline up to Period 3 Day 2 (maximum of 7 days)
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Abnormalities Without Regard to Baseline Abnormality
ParticipantsEntire Study Population
Eosinophils/Leukocytes (%) >1.2*ULN1
Monocytes/Leukocytes (%) >1.2*ULN2
Bicarbonate (mEq/L) <0.9*LLN1
Ketones (No Unit) >=11
URINE Hemoglobin (No Unit) >=11
Nitrite (No Unit) >=11
Leukocyte Esterase (No Unit) >=11
URINE Leukocytes (/HPF) >=201
Bacteria (/HPF) >201

Adverse events

Collected over Baseline (ie, post the first dose of study intervention) up to 35 days post last dose of study intervention (maximum of 40 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment A: Ritlecitinib 30 mg Intact Adult Capsule0/12 (0%)0/12 (0%)2/12 (16.7%)
Treatment B: Ritlecitinib 3*10 mg Pediatric Capsules0/12 (0%)0/12 (0%)1/12 (8.3%)
Treatment C: Ritlecitinib 30 mg Spray Congealed Beads0/12 (0%)0/12 (0%)1/12 (8.3%)
Most frequent other events
Most frequent other events
EventTreatment A: Ritlecitinib 30 mg Intact Adult CapsuleTreatment B: Ritlecitinib 3*10 mg Pediatric CapsulesTreatment C: Ritlecitinib 30 mg Spray Congealed Beads
Vessel puncture site painGeneral disorders2/120/120/12
FatigueGeneral disorders0/120/121/12
HeadacheNervous system disorders0/121/120/12
SomnolenceNervous system disorders0/121/120/12

Baseline characteristics

Includes all participants assigned to study intervention and who took at least 1 dose of study intervention.

Age, Continuous
Age, Continuous(Years)Entire Study Population
Median40.0 (23 to 56)
Age, Customized
Age, Customized(Participants)Entire Study Population
18-44 Years8
45-64 Years4
Sex: Female, Male
Sex: Female, Male(Participants)Entire Study Population
Female2
Male10
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Entire Study Population
White5
Black or African American3
Asian4
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Entire Study Population
Hispanic or Latino3
Not Hispanic or Latino9
08

Study locations

1 site
  • New Haven Clinical Research Unit
    New Haven, Connecticut 06511, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2021 to primary completion in Nov 2021, 2 months.

Results were first posted in Aug 2023, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 2, 2021
First posted
Sep 10, 2021
StartActual
Sep 10, 2021
Primary completionActual
Nov 19, 2021
CompletionActual
Nov 19, 2021
Results first posted
Aug 21, 2023
Last update
Aug 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05040295
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Sep 10, 2021
Start date
Sep 10, 2021
Primary completion
Nov 19, 2021
Completion
Nov 19, 2021
Results posted
Aug 21, 2023
Last update
Aug 21, 2023

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PF-06651600

Start the discussion